文献速递流行病学与生物统计临床试验与 GCP

评估羟氯喹、洛匹那韦-利托那韦或地塞米松治疗covid-19的观察性研究与随机对照试验治疗效果一致性:一项元流行病学研究

Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study.
PubMed 文献 · BMJ · 2022-05-10

该元流行病学研究系统识别、匹配并比较了评估羟氯喹、洛匹那韦-利托那韦或地塞米松治疗covid-19的观察性研究与随机对照试验的治疗效果。共形成27个匹配对,其中21个(78%)的治疗效果一致;二分类结局匹配对的一致比例(16/18,89%)高于连续结局匹配对(5/9,56%)。作者认为观察性研究的汇总证据可补充但不能替代随机对照试验证据。

要点

  • 27个匹配对中21个(78%)的观察性研究与随机对照试验治疗效果一致。
  • 二分类结局匹配对一致比例为89%(16/18),连续结局为56%(5/9)。
  • 作者认为观察性研究汇总证据可补充但不能替代随机对照试验证据。

核心结论

  • 评估covid-19治疗的观察性研究荟萃分析与随机对照试验的汇总治疗效果总体一致。
  • 作者认为观察性研究的荟萃分析证据可补充但不能替代随机对照试验证据。

研究设计与样本

  • 元流行病学研究,系统识别、匹配并比较评估羟氯喹、洛匹那韦-利托那韦或地塞米松治疗covid-19的观察性研究与随机对照试验。
  • 数据来源包括美国国立卫生研究院Covid-19治疗指南、The BMJ发表的一项活系统评价与网络荟萃分析、PLOS Medicine发表的活系统评价与荟萃分析及试验序贯分析(The LIVING Project)以及Epistemonikos的L·OVE证据数据库。
  • 纳入The BMJ活系统评价中直接比较三种最常研究治疗干预(羟氯喹、洛匹那韦-利托那韦或地塞米松)的随机对照试验,以及评估相同干预、比较和结局的观察性研究。
  • 共进行17项新的观察性研究独立荟萃分析,并与The BMJ活系统评价中的17项随机对照试验荟萃分析匹配;另识别10个仅含一项观察性研究和/或一项随机对照试验的匹配对,共计27个匹配对。

主要发现

  • 全部27个匹配对中,21个(78%)的治疗效果一致。
  • 17个由观察性研究荟萃分析与随机对照试验荟萃分析组成的匹配对中,14个(82%)一致。
  • 10个由至少一项观察性研究或一项随机对照试验组成的匹配对中,7个(70%)一致。
  • 18个二分类结局匹配对中16个(89%)一致,9个连续结局匹配对中5个(56%)一致。
  • 27个匹配对中22个对所有单项研究的人口学和临床数据报告充分,且这22个匹配对中所有研究在性别、年龄和疾病严重程度上分布重叠。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出其评估仅限于三种covid-19治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To systematically identify, match, and compare treatment effects and study demographics from individual or meta-analysed observational studies and randomized controlled trials (RCTs) evaluating the same covid-19 treatments, comparators, and outcomes. DESIGN: Meta-epidemiological study. DATA SOURCES: National Institutes of Health Covid-19 Treatment Guidelines, a living review and network meta-analysis published in The BMJ, a living systematic review with meta-analysis and trial sequential analysis in PLOS Medicine (The LIVING Project), and the Epistemonikos "Living OVerview of Evidence" (L·OVE) evidence database. ELIGIBILITY CRITERIA FOR SELECTION OF STUDIES: RCTs in The BMJ's living review that directly compared any of the three most frequently studied therapeutic interventions for covid-19 across all data sources (that is, hydroxychloroquine, lopinavir-ritonavir, or dexamethasone) for any safety and efficacy outcomes. Observational studies that evaluated the same interventions, comparisons, and outcomes that were reported in The BMJ's living review. DATA EXTRACTION AND SYNTHESIS: Safety and efficacy outcomes from observational studies were identified and treatment effects for dichotomous (odds ratios) or continuous (mean differences or ratios of means) outcomes were calculated and, when possible, meta-analyzed to match the treatment effects from individual RCTs or meta-analyses of RCTs reported in The BMJ's living review with the same interventions, comparisons, and outcomes (that is, matched pairs). The analysis compared the distribution of study demographics and the agreement between treatment effects from matched pairs. Matched pairs were in agreement if both observational and RCT treatment effects were significantly increasing or decreasing (P<0.05) or if both treatment effects were not significant (P≥0.05). RESULTS: 17 new, independent meta-analyses of observational studies were conducted that compared hydroxychloroquine, lopinavir-ritonavir, or dexamethasone with an active or placebo comparator for any safety or efficacy outcomes in covid-19 treatment. These studies were matched and compared with 17 meta-analyses of RCTs reported in The BMJ's living review. 10 additional matched pairs with only one observational study and/or one RCT were identified. Across all 27 matched pairs, 22 had adequate reporting of demographical and clinical data for all individual studies. All 22 matched pairs had studies with overlapping distributions of sex, age, and disease severity. Overall, 21 (78%) of the 27 matched pairs had treatment effects that were in agreement. Among the 17 matched pairs consisting of meta-analyses of observational studies and meta-analyses of RCTs, 14 (82%) were in agreement; seven (70%) of the 10 matched pairs consisting of at least one observational study or one RCT were in agreement. The 18 matched pairs with treatment effects for dichotomous outcomes had a higher proportion of agreement (n=16, 89%) than did the nine matched pairs with treatment effects for continuous outcomes (n=5, 56%). CONCLUSIONS: Meta-analyses of observational studies and RCTs evaluating treatments for covid-19 have summary treatment effects that are generally in agreement. Although our evaluation is limited to three covid-19 treatments, these findings suggest that meta-analyzed evidence from observational studies might complement, but should not replace, evidence collected from RCTs.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Moneer O, Daly G, Skydel JJ, et al. Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study. BMJ. 2022. PMID: 35537738. doi:10.1136/bmj-2021-069400

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。